Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
71 hedge funds and large institutions have $25.8M invested in Sio Gene Therapies Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 14 increasing their positions, 23 reducing their positions, and 31 closing their positions.
31% more capital invested
Capital invested by funds: $19.7M → $25.8M (+$6.13M)
12% less funds holding
Funds holding: 81 → 71 (-10)
32% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 31
39% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 23
42% less call options, than puts
Call options by funds: $1.25M | Put options by funds: $2.14M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.84M |
| 2 |
MWNA
Marshall Wace North America
New York
|
+$857K |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$591K |
| 4 |
Morgan Stanley
New York
|
+$455K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$363K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.24M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.92M |
| 3 |
Renaissance Technologies
New York
|
-$1.16M |
| 4 |
State Street
Boston,
Massachusetts
|
-$871K |
| 5 |
Millennium Management
New York
|
-$680K |
SIOX Hedge Fund Activity: Q2 2018 in Review
71 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q2 2018, worth a combined $25.8M — up 31% from $19.7M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of SIOX and 21 opened new positions — a net loss of 10 holders — while 23 trimmed existing stakes and 14 added.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $1.84M. The largest seller was BlackRock, cutting an estimated $3.24M.
- 71 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q2 2018, down from 81 in Q1 2018.
- Funds reported $25.8M of Sio Gene Therapies Inc. Common Stock stock for Q2 2018, up 31% quarter-over-quarter.
- 21 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q2 2018 and 31 closed out, a net change of -10 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q2 2018 was Adage Capital Partners, an estimated $1.84M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q2 2018 was BlackRock, an estimated $3.24M sold.
Based on aggregated 13F filings for Q2 2018.